Global Rivaroxaban Sales Market Report 2020

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.

Market Analysis and Insights: Global Rivaroxaban Market
The global Rivaroxaban market size is projected to reach US$ 12070 million by 2026, from US$ 7520.5 million in 2020, at a CAGR of 8.2% during 2021-2026.

Global Rivaroxaban Scope and Market Size
The global Rivaroxaban market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Rivaroxaban market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Rivaroxaban market is segmented into
2.5 mg
10 mg
15 mg
20 mg

Segment by Application, the Rivaroxaban market is segmented into
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)

The Rivaroxaban market is analysed and market size information is provided by regions (countries). Segment by Application, the Rivaroxaban market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Rivaroxaban Market Share Analysis
Rivaroxaban market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Rivaroxaban business, the date to enter into the Rivaroxaban market, Rivaroxaban product introduction, recent developments, etc.

The major vendors covered:
Bayer
J&J